Investment Analysts’ Weekly Ratings Updates for Collegium Pharmaceutical (COLL)

A number of firms have modified their ratings and price targets on shares of Collegium Pharmaceutical (NASDAQ: COLL) recently:

  • 4/16/2018 – Collegium Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $26.00 price target on the stock. According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
  • 4/4/2018 – Collegium Pharmaceutical was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 4/2/2018 – Collegium Pharmaceutical was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 3/28/2018 – Collegium Pharmaceutical was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 3/8/2018 – Collegium Pharmaceutical had its “outperform” rating reaffirmed by analysts at William Blair.
  • 3/8/2018 – Collegium Pharmaceutical had its price target raised by analysts at HC Wainwright from $21.00 to $33.00. They now have a “buy” rating on the stock.
  • 3/7/2018 – Collegium Pharmaceutical was upgraded by analysts at TheStreet from a “d+” rating to a “c” rating.
  • 2/23/2018 – Collegium Pharmaceutical was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of Collegium Pharmaceutical stock opened at $23.41 on Tuesday. The company has a market cap of $768.10, a PE ratio of -9.48 and a beta of 0.76. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $29.90.

How to Become a New Pot Stock Millionaire

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.02. The business had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The firm’s quarterly revenue was up 728.4% on a year-over-year basis. research analysts predict that Collegium Pharmaceutical will post -0.76 earnings per share for the current year.

In other news, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $22.50, for a total transaction of $450,000.00. Following the transaction, the chairman now directly owns 538,987 shares in the company, valued at approximately $12,127,207.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 25.76% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. lifted its holdings in Collegium Pharmaceutical by 21.5% in the fourth quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock valued at $29,833,000 after acquiring an additional 286,138 shares during the last quarter. LPL Financial LLC lifted its holdings in Collegium Pharmaceutical by 6.4% in the fourth quarter. LPL Financial LLC now owns 151,085 shares of the specialty pharmaceutical company’s stock valued at $2,789,000 after acquiring an additional 9,082 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Collegium Pharmaceutical by 11.3% in the fourth quarter. Teachers Advisors LLC now owns 66,533 shares of the specialty pharmaceutical company’s stock valued at $1,228,000 after acquiring an additional 6,739 shares during the last quarter. Raymond James & Associates acquired a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $389,000. Finally, California State Teachers Retirement System lifted its holdings in Collegium Pharmaceutical by 10.5% in the fourth quarter. California State Teachers Retirement System now owns 39,499 shares of the specialty pharmaceutical company’s stock valued at $729,000 after acquiring an additional 3,752 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply